News

Vera Therapeutics has announced an exclusive license agreement with Stanford University.

Stem cell biologist Helen Blau was recognized for her work on cellular plasticity and aging.

Synthekine Inc., which was founded on tech licensed from K. Christopher Garcia’s Stanford lab, today announced positive initial results from a first-in-human Phase 1 study.

Acoramidis is based on a Stanford technology licensed by Eidos Therapeutics, which BridgeBio acquired in 2021.

Valora, a biotech company pioneering a novel approach to immunotherapy, today announced the successful closing of its seed funding round.

Featured Story: A Revolution in Composites: Professor Stephen Tsai's Vision for a Lighter Future

Amid unprecedented demand for extreme-scale data centers, Lightmatter prepares for next phase of growth.

The newly published research highlights N-acetyltaurine's (NAT) potential for significant weight loss through appetite suppression.

The licensing agreement is for two promising metabolites with the potential to significantly improve metabolic health and naturally address the obesity epidemic.

Stanford’s High Impact Technology (HIT) Fund is kicking off its third year of helping researchers commercialize their most promising ideas.

Study to Evaluate MTX-101 for Safety, Pharmacokinetics, and Pharmacodynamics in Healthy Adults and Patients

This edition brings you our FY2023 Annual Report: "Lab to Life: Advancing Innovation"

SYNCAR-001 + STK-009 combination will be studied in two distinct lupus patient populations: non-renal systemic lupus erythematosus (SLE) and lupus nephritis (LN)

BridgeBio merged with Stanford Startup Eidos Therapeutics in 2021

They've entered into worldwide collaboration with Sanofi to develop and commercialize IL-10 receptor agonists for the treatment of inflammatory diseases.

Featured: InvinciKids & the Stanford Chariot Program deliver virtual reality alternatives for pediatric anesthesiology

Featured: Discussing the Promise and Future of RNA Medicines with Dr. Howard Chang